| 22.13 -1.78 (-7.44%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 30.83 | 1-year : | 36.01 |
| Resists | First : | 26.39 | Second : | 30.83 |
| Pivot price | 19.64  |
|||
| Supports | First : | 19.92 | Second : | 15.93 |
| MAs | MA(5) : | 22.45 |
MA(20) : | 18.98 |
| MA(100) : | 22.29 |
MA(250) : | 19.68 |
|
| MACD | MACD : | 1 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 63.4 |
D(3) : | 59.9 |
| RSI | RSI(14): 58.4 |
|||
| 52-week | High : | 37.26 | Low : | 6.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NGNE ] has closed below upper band by 22.4%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.46 - 25.59 | 25.59 - 25.71 |
| Low: | 21.72 - 21.85 | 21.85 - 21.97 |
| Close: | 21.91 - 22.14 | 22.14 - 22.33 |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Tue, 03 Mar 2026
Four new Neurogene hires receive options tied to stock price - Stock Titan
Fri, 27 Feb 2026
Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious - Seeking Alpha
Fri, 27 Feb 2026
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Fri, 27 Feb 2026
Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE) - Benzinga
Thu, 26 Feb 2026
FDA grants Breakthrough status to Neurogene (NGNE) Rett gene therapy - Stock Titan
Thu, 26 Feb 2026
Neurogene Inc. (NGNE) Stock Analysis: Exploring a Potential 184.72% Upside in the Biotech Sector - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 109.3 (%) |
| Shares Short | 3,590 (K) |
| Shares Short P.Month | 3,500 (K) |
| EPS | -4.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | -42.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.51 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -5.4 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|